{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:30Z","timestamp":1786993470081,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA129243"],"award-info":[{"award-number":["P01 CA129243"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtocrr.2025.100934","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:10:10Z","timestamp":1763766610000},"page":"100934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1036-9015","authenticated-orcid":false,"given":"Charles","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yakoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Offin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Ryum","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2025.100934_bib1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2025.100934_bib2","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the Phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100934_bib3","article-title":"Catalog of 5' fusion partners in ALK-positive NSCLC Circa 2020","volume":"1","author":"Ou","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2025.100934_bib4","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1158\/1541-7786.MCR-18-0171","article-title":"ALK fusion partners impact response to ALK inhibition: differential effects on sensitivity, cellular phenotypes, and biochemical properties","volume":"16","author":"Childress","year":"2018","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100934_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3580","article-title":"Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology","volume":"13","author":"Hallberg","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtocrr.2025.100934_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtocrr.2025.100934_bib7","doi-asserted-by":"crossref","first-page":"8599","DOI":"10.1200\/JCO.2024.42.16_suppl.8599","article-title":"Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC","volume":"42","author":"Thummalapalli","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100934_bib8","article-title":"Identification of Trim24 as a new NTRK3 fusion partner in lung adenocarcinoma: diagnostic challenges of a novel fusion","volume":"28","author":"Sant\u00f3n","year":"2022","journal-title":"Hum Pathol Rep"},{"key":"10.1016\/j.jtocrr.2025.100934_bib9","article-title":"Catalog of 5' fusion partners in RET+ NSCLC Circa 2020","volume":"1","author":"Ou","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2025.100934_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00385","article-title":"Novel TRIM24-MET fusion in a neonatal brain tumor","volume":"3","author":"Hiemenz","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtocrr.2025.100934_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jtocrr.2025.100934_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.tranon.2018.09.013","article-title":"MYC amplification as a potential mechanism of primary resistance to crizotinib in ALK-rearranged non-small cell lung cancer: a brief report","volume":"12","author":"Rihawi","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jtocrr.2025.100934_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.humgen.2023.201185","article-title":"MYC and non-small cell lung cancer: a comprehensive review","volume":"37","author":"Eftekhari Kenzerki","year":"2023","journal-title":"Hum Gene"},{"key":"10.1016\/j.jtocrr.2025.100934_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/OTT.S366627","article-title":"Spotlight on new therapeutic opportunities for MYC-driven cancers","volume":"16","author":"D\u2019Avola","year":"2023","journal-title":"Onco Targets Ther"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325001523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325001523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:27:16Z","timestamp":1773455236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364325001523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666364325001523"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100934","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100934"}}